Get started
Author

Elena Burroni

Observed names: Burroni, Elena, E Burroni, E. Burroni
ORCID: 0000-0002-1314-9600
Observed ORCID: 0000-0002-1314-9600
OpenAlex ID: A5009890257
Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy
2010 · Francesca M. Carozzi, Maria L. Tornesello, et al. · Cancer Epidemiology Biomarkers & Prevention · 76
Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference
2016 · Paolo Giorgi Rossi, Francesca Carozzi, et al. · Preventive Medicine · 66
PDF
Comparison of Clinical Performance of Abbott RealTi m e High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting
2011 · F. M. Carozzi, E. Burroni, et al. · Journal of Clinical Microbiology · 53
Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy
2018 · Francesca Carozzi, Donella Puliti, et al. · BMC Infectious Diseases · 47
PDF
Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence
2014 · Francesca Carozzi, Laura De Marco, et al. · Journal of Clinical Virology · 34
Distribution of high and low risk HPV types by cytological status: a population based study from Italy
2011 · Paolo Giorgi Rossi, Francesco Chini, et al. · Infectious Agents and Cancer · 32
PDF
Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study
2013 · Anna Gillio-Tos, Laura De Marco, et al. · Journal of Clinical Microbiology · 29
Human papilloma virus genotyping for the cross‐sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more
2018 · Annarosa Del Mistro, Rachael Adcock, et al. · International Journal of Cancer · 28
PDF
Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening
2014 · Elena Burroni, Paolo Bonanni, et al. · Journal of Medical Virology · 27
A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18–26 years
2013 · Cristina Giambi, Serena Donati, et al. · BMC Infectious Diseases · 26
PDF
HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies
2012 · the HPV Prevalence Italian Working Group, Paolo Giorgi Rossi, et al. · Infectious Agents and Cancer · 24
PDF
HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance
2015 · Francesca Maria Carozzi, Annarosa Del Mistro, et al. · Journal of Clinical Virology · 19
hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy
2013 · F Carozzi, C B Visioli, et al. · British Journal of Cancer · 18
PDF
Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix
2012 · E. Burroni, S. Bisanzi, et al. · Journal of Medical Virology · 16
Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
2015 · Francesca Carozzi, Lara Tamburrino, et al. · Journal of Cancer Research and Clinical Oncology · 15
Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology
2025 · Silvia Gori, Francesco Venturelli, et al. · British Journal of Cancer · 14
Effectiveness of HPV vaccination in women reaching screening age in Italy
2016 · F.M. Carozzi, C. Ocello, et al. · Journal of Clinical Virology · 14
Implementation of a centralized HPV-based cervical cancer screening programme in Tuscany: First round results and comparison with the foregoing Pap-based screening programme
2022 · Francesca Carozzi, Elena Burroni, et al. · Journal of Medical Screening · 10
Pool testing on random and natural clusters of individuals: Optimisation of SARS-CoV-2 surveillance in the presence of low viral load samples
2021 · Michela Baccini, Emilia Rocco, et al. · PLoS ONE · 10
Hybrid capture 2 and cobas® 4800: Comparison of performance of two clinically validated tests for human papillomavirus primary screening of cervical cancer
2021 · A Mongia, G Pompeo, et al. · Journal of Medical Screening · 6
Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women
2013 · Miriam Levi, Paolo Bonanni, et al. · Human Vaccines & Immunotherapeutics · 5
PDF
Developing evidence-based Multisociety Italian Guidelines for cervical cancer prevention: rationale, methods, and development process
2021 · Francesco Venturelli ), Paolo Giorgi Rossi, et al. · European Journal of Gynaecological Oncology · 3
Assessment of the feasibility of pool testing for SARS-CoV-2 infection screening
2022 · Irene Paganini, Cristina Sani, et al. · Scandinavian Journal of Infectious Diseases · 2
[HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].
2016 · Elena Burroni, Cristina Sani, et al. · PubMed · 2
Correction: Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology
2025 · Silvia Gori, Francesco Venturelli, et al. · British Journal of Cancer · 1
PDF
Works count: 33
Citation count: 577
H-index: 15
I10-index: 19
Year
Topic
Type